Background
Smokeless tobacco products | Regions (WHO) | Countries (highest consumption) | Other ingredients | Preparation and use | pHa | Nicotinea (mg/g) | Total TSNAa (ng/g) |
---|---|---|---|---|---|---|---|
Snus (Swedish) | Europe (Region A) | Nordic countries (Denmark, Finland, Iceland, Norway, Sweden) | Water, sodium carbonate, sodium chloride, moisturisers, flavouring | A heat treatment process; placed between the gum and upper lip | 6.6–7.2 | 7.8–15.2 | 601–723 |
Plug, Snuff (US), Snus (US) | Americas (Region A and B) | US, Canada, Mexico | Sweeteners, liquorice | Plug; air cured | 4.7–7.8 | 3.9–40.1 | 313–76,500 |
Dry or moist snuff; finely ground and fire cured | |||||||
Snus; steam cured | |||||||
Snuff; kept between lip and gum, dry snuff can be inhaled too | |||||||
Chimó | Americas (Region B) | Venezuela, Colombia | Sodium bicarbonate, brown sugar, Mamo’n tree ashes | Tobacco paste made from tobacco leaves; placed between the lip or cheek and gum and left there for some time | 6.9–9.4 | 5.3–30.1 | 9390 |
Nass (Naswar) | Europe (Region B) and Eastern Mediterranean (Region D) | Uzbekistan, Kyrgyzstan, Tajikistan, Afghanistan, Pakistan, Iran | Lime, ash, flavourings (cardamom), indigo | Sundried and powdered; placed between lip or cheek and gum | 8.4–9.1 | 8.9–14.2 | 478–1380 |
Tambook | Eastern Mediterranean (Region D) and Africa (Region D) | Sudan, Chad | Mixed with moist sodium bicarbonate | Fermented and grounded; placed and kept in mouth | 7.3–10.1 | 9.6–28.2 | 302,000–992,000 |
Snuff (North and West African) | Africa (Region D) | Nigeria, Ghana, Algeria, Cameroon, Chad, Senegal | Dried tobacco leaves mixed with potassium nitrate and other salts | Dry snuff; finely ground and inhaled as a pinch | 9.0–9.4 | 2.5–7.4 | 1520–2420 |
Moist snuff is placed in mouth | |||||||
Snuff (South African) | Africa (Region E) | South Africa | Dried tobacco leaves mixed with ash | Dry snuff; finely ground and inhaled as a pinch | 6.5–10.1 | 1.2–17.2 | 1710–20,500 |
Khaini | South East Asia (Regions B and D) Western Pacific (Region B) Eastern Mediterranean (Region D) Europe (Region A) | India, Bangladesh, Nepal, Bhutan | Slaked lime, menthol, flavourings, areca nut | Shredded; kept in mouth between lips and gum | 9.6–9.8 | 2.5–4.8 | 21,600–23,900 |
Zarda | Bangladesh, India, Pakistan, Myanmar, Thailand, Indonesia, Nepal, Maldives, Sri Lanka, UK | Served wrapped in a betel leaf with lime, catechu, areca nuts | Shredded tobacco leaves are boiled with lime and saffron; the mixture is dried then chewed and spat | 5.2–6.5 | 9.5–30.4 | 5490–53,700 | |
Gutkha | India, Pakistan, Bangladesh, Nepal, Myanmar, Sri Lanka, UK | Betel nut, catechu, flavourings, sweeteners | Commercially manufactured; sucked, chewed, and spat | 7.4–8.9 | 0.2–4.2 | 83–23,900 |
Methods
Prevalence of smokeless tobacco use
Diseases caused by smokeless tobacco use
Assessing risk and meta-analyses
Population attributable fraction
Overall burden
Attributable burden
Results
Prevalence of smokeless tobacco use
WHO sub-regions | Country | M | F | Source | Year |
---|---|---|---|---|---|
Africa (Region D) | Algeria | 21 | 0.4 | STEPS [38] | 2005 |
Benin | 12.7 | 5.7 | STEPS [38] | 2008 | |
Burkina Faso | – | 3.86 | DHS [39] | 2011 | |
Cameroon | 1.94 | 0.94 | DHS [39] | 2011 | |
Cape Verde | 3.5 | 5.8 | STEPS [38] | 2007 | |
Chad | 1.9 | 0.4 | STEPS [38] | 2008 | |
Comoros | 7.72 | 2.99 | DHS [39] | 2012 | |
Gabon | 0.48 | 0.34 | DHS [39] | 2012 | |
Gambia | 0.8 | 1.4 | STEPS [38] | 2010 | |
Ghana | 1.33 | 0.2 | DHS [39] | 2008 | |
Guinea | 1.4 | 1.5 | STEPS [38] | 2009 | |
Liberia | 2.3 | 2.4 | DHS [40] | 2007 | |
Madagascar | 24.66 | 19.6 | DHS [39] | 2009 | |
Mali | 5 | 1.2 | STEPS [38] | 2007 | |
Mauritania | 5.7 | 28.3 | STEPS [38] | 2006 | |
Niger | 4.55 | 2.3 | DHS [39] | 2012 | |
Nigeria | 3.2 | 0.5 | DHS [40] | 2008 | |
Sao Tome & Principe | 3.8 | 1.9 | STEPS [38] | 2009 | |
Senegal | 6.63 | 0.23 | DHS [39] | 2011 | |
Sierra Leone | 3 | 12 | STEPS [38] | 2009 | |
Togo | 5.1 | 2.2 | STEPS [38] | 2010 | |
Africa (Region E) | Botswana | 7.2 | 14.5 | STEPS [38] | 2007 |
Burundi | 0.03 | 0.31 | DHS [39] | 2011 | |
Congo (Brazzaville) | 8.3 | 1.54 | DHS [39] | 2012 | |
Congo (Republic) | 8.67 | 3.22 | DHS [39] | 2013 | |
Cote d'Ivoire | 0.61 | 1.27 | DHS [39] | 2012 | |
Eritrea | 5.8 | 0.2 | STEPS [38] | 2004 | |
Ethiopia | 1.94 | 0.2 | DHS [39] | 2011 | |
Kenya | 2.05 | 1.29 | DHS [39] | 2008 | |
Lesotho | 1.3 | 9.1 | DHS [40] | 2009 | |
Malawi | 1.9 | 5 | STEPS [38] | 2009 | |
Mozambique | 10.94 | 0.82 | DHS [39] | 2011 | |
Namibia | 1.8 | 2.3 | DHS [40] | 2006–07 | |
Rwanda | 5.8 | 2.73 | DHS [39] | 2011 | |
South Africa | 2.4 | 10.9 | DHS [41] | 2003 | |
Swaziland | 2.6 | 0.8 | STEPS [38] | 2007 | |
Tanzania | 2.03 | 0.83 | DHS [39] | 2010 | |
Uganda | 2.94 | 1.5 | DHS [39] | 2011 | |
Zambia | 0.3 | 1.2 | DHS [39] | 2007 | |
Zimbabwe | 1.6 | 0.4 | DHS [41] | 2011 | |
Americas (Region A) | Canada | 2 | – | ICS [41] | 2011 |
USA | 6.5 | 0.4 | ICS [41] | 2010 | |
Americas (Region B) | Argentina | 0.1 | 0.2 | GATS [42] | 2012 |
Barbados | 0 | 0.6 | STEPS [38] | 2007 | |
Brazil | 0.6 | 0.3 | GATS [42] | 2010 | |
Dominican Republic | 1.9 | 0.3 | DHS [40] | 2007 | |
Grenada | 2.2 | 0.3 | STEPS [38] | 2011 | |
Mexico | 0.3 | 0.3 | GATS [42] | 2009 | |
Paraguay | 3 | 1.6 | ICS [41] | 2011 | |
St Kitts & Nevisa | 0.3 | 0.1 | STEPS [38] | 2007 | |
Trinidad & Tobago | 0.5 | 0.3 | STEPS [38] | 2011 | |
Venezuela | 6.2 | 0.9 | ICS [41] | 2011 | |
Americas (Region D) | Haiti | – | 2.5 | DHS [40] | 2005–06 |
Eastern Mediterranean (Region B) | Libya | 2.2 | 0.1 | STEPS [38] | 2009 |
Saudi Arabia | 1.3 | 0.5 | STEPS [38] | 2004 | |
Tunisia | 8.6 | 2.2 | ICS [41] | 2005–06 | |
Eastern Mediterranean (Region D) | Egypt | 4.8 | 0.3 | GATS [42] | 2009 |
Iraq | 1.6 | 0.3 | STEPS [38] | 2006 | |
Pakistan | 16.3 | 2.44 | DHS [43] | 2012–13 | |
Sudan | 24.1 | 1 | STEPS [38] | 2005 | |
Yemen | 15.1 | 6.2 | ICS [41] | 2003 | |
Europe (Region A) | Austria | 7.8 | 1.1 | SEBS [44] | 2012 |
Belgium | 1.1 | 0.6 | SEBS [44] | 2012 | |
Cyprus | 2.1 | 0.4 | SEBS [44] | 2012 | |
Czech Republic | 2.5 | 0.4 | SEBS [44] | 2012 | |
Denmark | 3 | 1 | ICS [41] | 2010 | |
Finland | 5.5 | 0.3 | ICS [41] | 2011 | |
France | 1.2 | 0.6 | SEBS [44] | 2012 | |
Germany | 3.4 | 3.4 | SEBS [44] | 2012 | |
Iceland | 5.97 | – | ICS [41] | 2008 | |
Ireland | 2.2 | 0.9 | SEBS [44] | 2012 | |
Italy | 1.8 | 1.5 | SEBS [44] | 2012 | |
Luxembourg | 1.8 | 1 | SEBS [44] | 2012 | |
Malta | 5.5 | 1.5 | SEBS [44] | 2012 | |
Netherlands | 0.3 | 0.1 | ICS [41] | 2011 | |
Norway | 20 | 6 | ICS [41] | 2011 | |
Portugal | 4.4 | 1.1 | SEBS [44] | 2012 | |
Slovenia | 1.8 | 0.4 | SEBS [44] | 2012 | |
Spain | 0.4 | 0.2 | SEBS [44] | 2012 | |
Sweden | 24 | 7 | ICS [41] | 2011 | |
Switzerland | 4 | 1.3 | ICS [41] | 2011 | |
United Kingdom | 1.6 | 0.5 | SEBS [44] | 2012 | |
Europe (Region B) | Ajerbaijan | 0.3 | 0 | DHS [40] | 2006 |
Armenia | 1.8 | 0 | DHS [40] | 2005 | |
Bulgaria | 0.3 | 0 | SEBS [44] | 2012 | |
Georgia | 1 | 0.2 | ICS [41] | 2010 | |
Kyrgyzstan | 7 | 0.3 | ICS [41] | 2006 | |
Poland | 1 | 0.1 | GATS [42] | 2009 | |
Romania | 0.4 | 0.2 | GATS [42] | 2011 | |
Slovakia | 3.9 | 0.7 | SEBS [44] | 2012 | |
Uzbekistan | 31.8 | 0.2 | DHS [40] | 2002 | |
Europe (Region C) | Latvia | 5.8 | 0.9 | ICS [41] | 2010 |
Lithuania | 1.2 | 0.2 | SEBS [44] | 2012 | |
Moldova | 0.1 | 0 | DHS [40] | 2005 | |
Russia | 1 | 0.2 | GATS [42] | 2009 | |
Ukraine | 0.5 | 0 | GATS [42] | 2010 | |
South East Asia (Region B) | Indonesia | 1.5 | 2 | GATS [42] | 2011 |
Sri Lanka | 24.9 | 6.9 | STEPS [38] | 2006 | |
Thailand | 1.1 | 5.2 | GATS [42] | 2011 | |
South East Asia (Region D) | Bangladesh | 26.4 | 27.9 | GATS [42] | 2009 |
Bhutan | 21.1 | 17.3 | STEPS [38] | 2007 | |
India | 32.9 | 18.4 | GATS [42] | 2009 | |
Maldives | 5.6 | 2.6 | STEPS [38] | 2011 | |
Myanmar | 51.4 | 16.1 | STEPS [38] | 2009 | |
Nepal | 37.9 | 6 | DHS [41] | 2011 | |
Timor Leste | 2.48 | 1.93 | DHS [43] | 2009–10 | |
Western Pacific (Region A) | Australia | 0.75 | 0.41 | ICS [45] | 2004 |
Western Pacific (Region B) | Cambodia | 2.2 | 14.8 | STEPS [38] | 2010 |
China | 0.7 | 0 | GATS [42] | 2010 | |
Lao People’s Democratic Republic | 14.6 | 1.1 | STEPS [38] | 2008 | |
Malaysia | 0.9 | 0.6 | GATS [42] | 2011 | |
Micronesia | 22.4 | 3 | STEPS [38] | 2002 | |
Mongolia | 2.8 | 0.5 | STEPS [38] | 2009 | |
Philippines | 2.8 | 1.2 | GATS [42] | 2009 | |
Vietnam | 0.3 | 2.3 | GATS [42] | 2010 |
Diseases caused by smokeless tobacco use
Country | Study period | Study design | Exposure status | Inclusion of cigarette/alcohol users | Outcome | Odds ratios/relative risks (95 % confidence intervals) | Comments | Quality assessment (NOS)a | Reference |
---|---|---|---|---|---|---|---|---|---|
CANCERS | |||||||||
India | 2001–2004 | Case–control | Smokeless tobacco with or without additives | No/No | Oral cancer | 0.49 (0.32–0.75) | Exclusive SLT users | Selection**** | Anantharaman et al. 2007 [46] |
Comparability** | |||||||||
Exposure/Outcome* | |||||||||
India | 1996–1999 | Case–control | Ever SLT users | Yes/Yes | Oral cancer | 7.31 (3.79–14.1) | Never drinkers adjusted for smoking | Selection**** | Balaram et al. 2002 [47] |
9.19 (4.38–19.28) | Never smokers adjusted for alcohol | Comparability** | |||||||
Exposure/Outcome * | |||||||||
India | 1982–1992 | Case–control | Tobacco quid chewing | Yes/No | Oral cancer | 5.8 (3.6–9.34) | Adjusted for smoking | Selection*** | Dikshit & Kanhere 2000 [48] |
Pharyngeal cancer | 1.2 (0.8–1.8) | Comparability* | |||||||
Lung cancer | 0.7 (0.4–1.22) | Exposure/Outcome* | |||||||
India | Unclear | Case–control | Chewing tobacco | No/No | Oral cancer | 10.75 (6.58–17.56) | Exclusive SLT users | Selection** | Goud et al. 1990 [49] |
Comparability* | |||||||||
Exposure/Outcome0 | |||||||||
India | 1990–1997 | Cohort | Current SLT users | No/No | Oral cancer | 5.5 (3.3–9.17) | Exclusive SLT users | Selection**** | Jayalekshmi et al. 2009 [50] |
Former SLT users | 9.2 (4.6–18.40) | Comparability* | |||||||
Exposure/Outcome** | |||||||||
India | 1990–1997 | Cohort | Current SLT user | Yes/Yes | Oral cancer | 2.4 (1.7–3.39) | Adjusted for smoking and alcohol | Selection**** | Jayalekshmi et al. 2010 [51] |
Former SLT users | 2.1 (1.3–3.39) | Comparability* | |||||||
Exposure/Outcome*** | |||||||||
India | May 2005 | Case–control | Ever SLT users | No/No | Oral cancer | 4.23 (3.11–5.75) | Exclusive SLT users | Selection*** | Jayant et al. 1977 [52] |
Pharyngeal cancer | 2.42 (1.74–3.37) | Comparability** | |||||||
Laryngeal cancer | 2.8 (2.07–3.79) | Exposure/Outcome0 | |||||||
Oesophageal cancer | 1.55 (1.15–2.07) | ||||||||
India | 1968 | Case–control | Tobacco | Yes/No | Oral cancer | 4.63 (3.50–6.14) | Exclusive chewers and non-chewers data available | Selection*** | Jussawalla & Deshpande 1971 [53] |
Pharyngeal cancer | 3.09 (2.31–4.13) | Comparability** | |||||||
Laryngeal cancer | 2.29 (1.72–3.05) | Exposure/Outcome0 | |||||||
Oesophageal cancer | 3.82 (2.84–5.13) | ||||||||
India | 2005–2006 | Case–control | Tobacco flakes | Yes/Yes | Oral cancer | 7.6 (4.9–11.79) | Adjusted for smoking and alcohol | Selection**** | Madani et al. 2010 [54] |
Gutkha | 12.7 (7–23.04) | Comparability** | |||||||
Mishiri | 3.0 (1.9–4.74) | Exposure/Outcome* | |||||||
India | Unclear | Case–control | Chewing tobacco | Yes/Yes | Oral cancer | 5.0 (3.6–6.94) | Adjusted for smoking and alcohol | Selection**** | Muwonge et al. 2008 [55] |
Comparability* | |||||||||
Exposure/Outcome* | |||||||||
India | 1982–1984 | Case–control | Chewing tobacco | Yes/No | Oral cancer | 10.2 (2.6–40.02) | Adjusted for smoking | Selection*** | Nandakumar et al. 1990 [56] |
Comparability** | |||||||||
Exposure/Outcome* | |||||||||
India | 1980–1984 | Case–control | SLT users | No/No | Oral cancer | 1.99 (1.41–2.81) | Exclusive SLT users | Selection** | Rao et al. 1994 [57] |
Comparability0 | |||||||||
Exposure/Outcome* | |||||||||
India | 1952–1954 | Case–control | Chewing tobacco | No/No | Oral cancer | 4.85 (2.32–10.14) | Exclusive SLT users | Selection*** | Sanghvi et al. 1955 [58] |
Pharyngeal cancer | 2.02 (0.94–4.33) | Comparability** | |||||||
Laryngeal cancer | 0.76 (0.37–1.56) | Exposure/Outcome0 | |||||||
India | 1983–1984 | Case–control | Snuff (males only) | Yes/Yes | Oral cancer | 2.93 (0.98–8.76) | Adjusted for smoking and alcohol; adjusted effect size is only among males | Selection*** | Sankaranarayan et al. 1990 [59] |
Comparability0 | |||||||||
Exposure/Outcome* | |||||||||
India | Not given | Case–control | Tobacco chewing | Yes/Yes | Oropharyngeal cancer | 7.98 (4.11–13.58)b | Adjusted for smoking and alcohol | Selection*** | Wasnik et al. 1998 [60] |
Comparability** | |||||||||
Exposure/Outcome0 | |||||||||
India | 1991–2003 | Case–control | Chewing tobacco | No/No | Oral cancer | 5.88 (3.66–7.93) | Exclusive SLT users | Selection**** | Subapriya e al. 2007 [61] |
Comparability** | |||||||||
Exposure/Outcome** | |||||||||
India | 1950–1962 | Case–control | Tobacco with or without paan or lime | Yes/No | Oral and oropharyngeal cancer | 41.90 (34.20–51.33) | Exclusive chewer data available | Selection** | Wahi et al. 1965 [62] |
Note: data of habit was not available for the whole cohort | Comparability** | ||||||||
Exposure/Outcome0 | |||||||||
Pakistan | 1996–1998 | Case–control | Naswar | Yes/Yes | Oral cancer | 9.53 (1.73–52.50) | Adjusted for smoking and alcohol | Selection*** | Merchant et al. 2000 [63] |
Paan with tobacco | 8.42 (2.31–30.69) | Comparability** | |||||||
Exposure/Outcome* | |||||||||
Sweden | 1973–2002 | Cohort | Snus | Yes/Yes | Oral and pharyngeal combined | 3.10 (1.50–6.41) | Adjusted for smoking and alcohol | Selection** | Roosar et al. 2008 [64] |
Comparability** | |||||||||
Outcome*** | |||||||||
India | 1993–1999 | Case–control | Chewing tobacco | Yes/Yes | Oral cancer | 5.05 (4.26–5.99) | Adjusted for smoking and alcohol | Selection*** | Znaor et al. 2003 [65] |
Pharynx | 1.83 (1.43–2.34) | Comparability** | |||||||
Oesophagus | 2.06 (1.62–2.62) | Exposure/Outcome* | |||||||
Norway | 1966–2001 | Cohort | Chewing tobacco plus oral snuff | No/No | Oral cancer | 1.1 (0.5–2.42) | Adjusted for smoking, might be confounded by alcohol use | Selection*** | Bofetta et al. 2005 [66] |
Oesophageal cancer | 1.4 (0.61–3.21) | Comparability* | |||||||
Pancreatic cancer | 1.67 (1.12–2.49) | Exposure/Outcome*** | |||||||
Lung cancer | 0.80 (0.61–1.05) | ||||||||
Sweden | 1988–1991 | Case–control | Oral snuff | Yes/Yes | Oral cancer | 1.4 (0.8–2.45) | Adjusted for smoking and alcohol | Selection** | Lewin et al. 1998 [67] |
Larynx | 0.9 (0.5–1.62) | Comparability** | |||||||
Oesophagus | 1.2 (0.7–2.06) | Exposure/Outcome* | |||||||
Pharynx | 0.7 (0.4–1.22) | ||||||||
Sweden | 1969–1992 | Cohort | Snus | No/No | Oral cancer | 0.8 (0.4–1.60) | Exclusive SLT users | Selection*** | Luo et al. 2007 [68] |
Lung cancer | 0.8 (0.5–1.28) | Comparability* | |||||||
Pancreatic cancer | 2 (1.20–3.33) | Exposure/Outcome*** | |||||||
Sweden | 2000–2004 | Case–control | Oral snuff | Yes/Yes | Oral | 0.70 (0.3–1.63) | Adjusted for smoking and alcohol | Selection*** | Rosenquist et al 2005 [69] |
Comparability** | |||||||||
Exposure/Outcome** | |||||||||
Sweden | 1980–1989 | Case–control | Oral snuff | Yes/Yes | Oral cancer | 0.8 (0.5–1.28) | Adjusted for smoking and alcohol | Selection** | Schildt et al. 1998 [70] |
Comparability** | |||||||||
Exposure/Outcome*** | |||||||||
USA | 1972–1983 | Case–control | Oral snuff | Yes/Yes | Oral cancer | 0.8 (0.4–1.60) | Not clear if adjusted for smoking and alcohol | Selection** | Mashberg et al. 1993 [71] |
Chewing tobacco | 1 (0.7–1.43) | Comparability0 | |||||||
Exposure/Outcome* | |||||||||
USA | Not given | Case–control | SLT use | Yes/Yes | Oral cancer | 0.90 (0.38–2.13) | Adjusted for smoking and alcohol | Selection*** | Zhou et al. 2013 [15] |
Pharyngeal cancer | 1.59 (0.84–3.01) | Comparability** | |||||||
Laryngeal cancer | 0.67 (0.19–2.36) | Exposure/Outcome* | |||||||
India | 2001–2004 | Case–control | Chewing tobacco | No/No | Pharyngeal cancer | 3.18 (1.92–5.27) | Exclusive SLT users | Selection*** | Sapkota et al. 2007 [72] |
Laryngeal cancer | 0.95 (0.52–1.74) | Comparability** | |||||||
Exposure/Outcome* | |||||||||
Pakistan | 1998–2002 | Case–control | Snuff dipping | No/No | Oesophageal cancer | 4.1 (1.3–12.93) | Adjusted for areca nut | Selection*** | Akhtar et al. 2012 [73] |
Quid with tobacco | 14.2 (6.4–31.50) | Comparability** | |||||||
Exposure/Outcome** | |||||||||
India | 2008–2012 | Case–control | Nass chewing | No/No | Oesophageal cancer | 2.88 (2.06–4.03) | Exclusive SLT users | Selection*** | Dar et al. 2012 [74] |
Gutkha chewing | 2.87 (0.87–9.47) | Comparability** | |||||||
Exposure/Outcome** | |||||||||
India | 2007–2011 | Case–control | Oral snuff | Yes/Yes | Oesophageal cancer | 3.86 (2.46–6.06) | Adjusted for smoking and alcohol | Selection** | Sehgal et al. 2012 [75] |
Comparability** | |||||||||
Exposure/Outcome* | |||||||||
India | 2011–2012 | Case–control | Chewing tobacco | Yes/Yes | Oesophageal cancer | 2.63 (1.53–4.52) | Adjusted for smoking and alcohol | Selection*** | Talukdar et al. 2013 [76] |
Comparability** | |||||||||
Exposure/Outcome* | |||||||||
Sweden | 1995–1997 | Case–control | Oral snuff | Yes/Yes | Oesophageal cancer (adenocarcinoma) | 1.2 (0.7–2.06) | Adjusted for smoking and alcohol | Selection*** | Lagergren et al. 2000 [77] |
(Squamous cell carcinoma) | 1.4 (0.9–2.18) | Comparability** | |||||||
Exposure/Outcome* | |||||||||
Sweden | 1969–1993 | Cohort | Oral snuff | Yes/No | Oesophageal cancer (Adenocarcinoma) | 1.3 (0.8–2.11) | Adjusted for smoking | Selection** | Zendehdel et al. 2008 [78] |
(Squamous cell carcinoma) | 1.2 (0.8–1.80) | Comparability* | |||||||
Exposure/Outcome** | |||||||||
Sweden | 1974–1985 | Cohort | SLT users | No/NA | Lung cancer | 0.90 (0.20– 4.05) | Adjusted for age, region of origin | Selection*** | Bolinder et al. 1994 [79] |
Comparability* | |||||||||
Outcome** | |||||||||
Morocco | 1996–1998 | Case–control | SLT users | Yes/No | Lung cancer | 1.05 (0.28–3.94) | Adjusted for smoking | Selection** | Sasco et al. 2002 [80] |
Comparability** | |||||||||
Exposure/Outcome** | |||||||||
USA | 1977–1984 | Case–control | SLT users | Yes/No | Oesophageal cancer | 1.2 (0.1–14.40) | Adjusted for smoking | Selection*** | Brown et al. 1988 [81] |
Comparability** | |||||||||
Exposure/Outcome** | |||||||||
USA | 1986–1989 | Case–control | SLT users | Yes/No | Pancreatic cancer | 1.4 (0.5–3.92) | Adjusted for smoking | Selection*** | Alguacil & Silverman 2004 [82] |
Comparability* | |||||||||
Exposure/Outcome** | |||||||||
USA | 2000–2006 | Case–control | Chewing tobacco | Yes/Yes | Pancreatic cancer | 0.6 (0.3–1.20) | Adjusted for smoking and alcohol | Selection**** | Hassan et al. 2007 [83] |
Oral snuff | 0.5 (0.1–2.5) | Comparability** | |||||||
Exposure/Outcome* | |||||||||
CARDIOVASCULAR DISEASES (ischaemic heart disease and stroke) | |||||||||
52 countries | 1999–2003 | Case–control | Chewing tobacco | No/Yes | Myocardial infarction | 1.57 (1.24–1.99) | Adjusted for diabetes, abdominal obesity, hypertension, exercise, diet | Selection**** | Teo et al. 2006 [29] |
Comparability** | |||||||||
Exposure/Outcome* | |||||||||
Pakistan | 2005–2011 | Case–control | Dippers only (Naswar) | No/NA | Myocardial infarction | 1.46 (1.20–1.77) | Adjusted for age, sex, region, ethnicity | Selection**** | Alexander 2013 [84] |
Chewers only (Paan/ Supari/ Gutkha) | 1.71 (1.46–2.00) | Comparability** | |||||||
Exposure/Outcome** | |||||||||
Bangladesh | 2006–2007 | Case–control | Ever SLT users | No/NA | Myocardial infarction, Angina pectoris | 2.8 (1.1–7.13) | Adjusted for age, sex, hypertension | Selection*** | Rahman & Zaman 2008 [85] |
Comparability** | |||||||||
Exposure/Outcome* | |||||||||
Bangladesh | 2010 | Case–control | Ever SLT users | No/NA | Myocardial infarction, Angina pectoris | 0.77 (0.52–1.14) | Adjusted for age, hypertension, diabetes, acute psycho-social stress | Selection**** | Rahman et al. 2012 [86] |
Comparability** | |||||||||
Exposure/Outcome* | |||||||||
Sweden | 1998–2005 | Case–control | Current SLT users | No/NA | Myocardial infarction | 0.73 (0.35–1.52) | Exclusive SLT users | Selection*** | Hergens et al. 2005 [87] |
Former SLT users | 1.2 (0.46–3.13) | Comparability** | |||||||
Exposure/Outcome** | |||||||||
Sweden | 1978–2004 | Cohort | Ever SLT users | No/NA | Myocardial infarction | 0.99 (0.90–1.10) | Adjusted for age, BMI, region of residence | Selection** | Hergens et al. 2007 [88] |
Comparability** | |||||||||
Exposure/Outcome*** | |||||||||
Sweden | 1989–1991 | Case–control | Regular SLT users | Yes/NA | Myocardial infarction | 1.01 (0.66–1.55)c | Adjusted for age, education, smoking | Selection*** | Huhtasaari et al. 1992 [89] |
Comparability** | |||||||||
Exposure/Outcome* | |||||||||
Sweden | 1991–1993 | Case–control | Former SLT users | No/NA | Myocardial infarction | 1.23 (0.54–2.82) | Exclusive SLT users | Selection**** | Huhtasaari et al. 1999 [90] |
Comparability** | |||||||||
Exposure/Outcome** | |||||||||
Sweden | 1988–2000 | Cohort | Daily SLT users | No/NA | Ischaemic heart disease | 1.41 (0.61–3.28) | Adjusted for BMI, physical activity, diabetes, hypertension | Selection**** | Johansson et al. 2005 [91] |
Comparability** | |||||||||
Exposure/Outcome** | |||||||||
Sweden | 1985–1999 | Case–control | Current SLT users | No/NA | Myocardial infarction | 0.82 (0.46–1.46) | Adjusted for BMI, physical activity, education, cholesterol | Selection**** | Wennberg et al. 2007 [92] |
Former SLT users | 0.66 (0.32–1.36) | Comparability** | |||||||
Exposure/Outcome** | |||||||||
Sweden | 1985–2000 | Case–control | Regular SLT users | No/NA | Stroke | 0.87 (0.41–1.83) | Adjusted for diabetes, hypertension, education, marital status, cholesterol | Selection**** | Asplund et al. 2003 [93] |
Comparability** | |||||||||
Exposure/Outcome** | |||||||||
Sweden | 1978–2003 | Cohort | Ever SLT users | No/NA | Stroke | 1.02 (0.92–1.13) | Adjusted for age, BMI, region of residence | Selection** | Hergens et al. 2008 [94] |
Comparability** | |||||||||
Exposure/Outcome*** | |||||||||
Sweden | 1998–2005 | Cohort | Current SLT users | No/NA | Ischaemic heart disease | 0.85 (0.51–1.42) | Adjusted for age, hypertension, diabetes, cholesterol | Selection*** | Hansson et al. 2009 [95] |
Former SLT users | Stroke | 1.07 (0.56–2.04) | Comparability** | ||||||
1.18 (0.67–2.08) | Exposure/Outcome** | ||||||||
1.35 (0.65–2.82) | |||||||||
Sweden | 1991–2004 | Cohort | SLT users | No/NA | Myocardial infarction | 0.75 (0.3–1.87) | Adjusted for age, diabetes, occupation, hypertension, physical activity, BMI, marital status | Selection*** | Janzon et al. 2009 [96] |
Stroke | 0.59 (0.2–1.5) | Comparability** | |||||||
Exposure/Outcome** |
Relative risks
Applying risk estimates
Attributable burden
WHO sub-regionsa | Mouth cancer | Pharyngeal cancer | Oesophageal cancer | Ischaemic heart disease | All causes | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | F | All | M | F | All | M | F | All | M | F | All | M | F | All | |
DEATHS | |||||||||||||||
Africa D | 86 | 36 | 123 | 15 | 2 | 17 | 157 | 77 | 233 | 2323 | 751 | 3074 | 2581 | 866 | 3448 |
Africa E | 155 | 85 | 240 | 19 | 12 | 31 | 389 | 252 | 641 | 1202 | 923 | 2125 | 1765 | 1272 | 3037 |
Americas A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10,240 | 649 | 10,889 | 10,240 | 649 | 10,889 |
Americas B | 90 | 11 | 102 | 28 | 3 | 31 | 74 | 9 | 83 | 1030 | 291 | 1321 | 1222 | 314 | 1536 |
Americas D | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Eastern Mediterranean B | 11 | 1 | 12 | 1 | 0 | 2 | 4 | 1 | 5 | 441 | 74 | 515 | 457 | 76 | 534 |
Eastern Mediterranean D | 933 | 254 | 1187 | 604 | 59 | 663 | 1012 | 129 | 1141 | 7401 | 926 | 8327 | 9950 | 1368 | 11,318 |
Europe A | 66 | 13 | 78 | 16 | 2 | 18 | 244 | 38 | 282 | 539 | 145 | 684 | 865 | 197 | 1062 |
Europe B | 146 | 3 | 148 | 57 | 1 | 58 | 260 | 2 | 262 | 5506 | 156 | 5662 | 5969 | 162 | 6130 |
Europe C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
South-East Asia B | 438 | 396 | 835 | 129 | 58 | 187 | 243 | 139 | 382 | 3205 | 1852 | 5057 | 4016 | 2445 | 6461 |
South-East Asia D | 11,527 | 6459 | 17,987 | 12,715 | 3485 | 16,200 | 15,247 | 5625 | 20,873 | 117,523 | 45,047 | 162,570 | 157,013 | 60,617 | 217,630 |
Western Pacific A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69 | 36 | 104 | 69 | 36 | 104 |
Western Pacific B | 134 | 159 | 293 | 22 | 34 | 56 | 51 | 63 | 114 | 3167 | 814 | 3981 | 3374 | 1070 | 4443 |
Worldwide | 13,586 | 7418 | 21,003 | 13,608 | 3656 | 17,264 | 17,680 | 6336 | 24,016 | 152,647 | 51,662 | 204,309 | 197,520 | 69,072 | 266,592 |
DALYs | |||||||||||||||
Africa D | 2516 | 1046 | 3562 | 452 | 65 | 517 | 4119 | 1906 | 6024 | 64,043 | 19,116 | 83,159 | 71,130 | 22,132 | 93,262 |
Africa E | 4926 | 2293 | 7220 | 573 | 349 | 922 | 10,159 | 6290 | 16,449 | 33,502 | 21,109 | 54,610 | 49,159 | 30,042 | 79,201 |
Americas A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 172,206 | 7213 | 179,419 | 172,206 | 7213 | 179,419 |
Americas B | 2311 | 230 | 2541 | 734 | 63 | 797 | 1717 | 176 | 1893 | 22,252 | 4728 | 26,980 | 27,014 | 5197 | 32,210 |
Americas D | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Eastern Mediterranean B | 285 | 36 | 321 | 33 | 9 | 43 | 86 | 20 | 106 | 9841 | 1383 | 11,224 | 10,246 | 1448 | 11,694 |
Eastern Mediterranean D | 29,240 | 7669 | 36,909 | 16,446 | 1800 | 18,247 | 27,777 | 3613 | 31,390 | 187,394 | 21,544 | 208,938 | 260,857 | 34,627 | 295,483 |
Europe A | 1514 | 224 | 1738 | 369 | 45 | 414 | 4949 | 545 | 5494 | 8397 | 1491 | 9888 | 15,230 | 2304 | 17,534 |
Europe B | 4439 | 60 | 4499 | 1704 | 20 | 1724 | 6460 | 56 | 6517 | 115,640 | 1991 | 117,631 | 128,243 | 2128 | 130,371 |
Europe C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
South-East Asia B | 10,968 | 7741 | 18,709 | 3217 | 1487 | 4704 | 5608 | 2983 | 8591 | 66,969 | 29,913 | 96,881 | 86,762 | 42,124 | 128,886 |
South-East Asia D | 351,752 | 179,051 | 530,803 | 338,976 | 107,041 | 446,017 | 400,770 | 143,146 | 543,916 | 290,6993 | 938,528 | 3,845,521 | 3,998,491 | 1,367,766 | 5,366,257 |
Western Pacific A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1024 | 340 | 1364 | 1024 | 340 | 1364 |
Western Pacific B | 3700 | 3567 | 7267 | 615 | 794 | 1409 | 1313 | 1485 | 2797 | 72,936 | 16,830 | 89,766 | 78,564 | 22,675 | 101,239 |
Worldwide | 411,652 | 201,918 | 613,569 | 363,120 | 111,673 | 474,793 | 462,957 | 160,219 | 623,177 | 3,661,195 | 1,064,186 | 4,725,381 | 4,898,924 | 1,537,996 | 6,436,920 |